Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2017

30.09.2016 | Inflammatory Disorders

Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis

verfasst von: Marc Breitbach, Christoph Tappeiner, Michael R. R. Böhm, Beatrix Zurek-Imhoff, Carsten Heinz, Solon Thanos, Gerd Ganser, Arnd Heiligenhaus

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to evaluate the discontinuation of adalimumab (ADA) treatment in patients with juvenile idiopathic arthritis-associated uveitis (JIAU).

Methods

Patients in whom ADA treatment was initiated for JIAU were included in this retrospective analysis. Reasons for discontinuing ADA treatment in patients with primary treatment response were analysed.

Results

Within a group of 387 JIAU patients, 59 of 68 patients who were treated with ADA achieved a sufficient response to treatment within 6 months. Here, 39 patients (66.1 %) were still on therapy at their last follow-up visit (mean treatment duration of 38.3 months, range 12–91). In another 20 patients, ADA had been discontinued after 1 or 2 years or later, in 10 % (n = 2), 45 % (n = 9) and 45 % (n = 9) of patients, respectively (mean 30.6 months; range 10–65). Reasons for discontinuing ADA were reactivation of uveitis (n = 8, 3.93 per 100 patient-years) or arthritis (n = 4; 1.97 per 100 patient-years), or ≥2 years of complete disease inactivity (n = 3, 1.47 per 100 patient-years), adverse events (n = 4; 1.89 per 100 patient-years), or other (n = 1; 0.47 per 100 patient-years).

Conclusions

The data show a good primary response to ADA in patients with refractory JIAU. Due to the increasing rate of adalimumab failure or adverse events during long-term treatment, further treatment options may be required.
Literatur
1.
Zurück zum Zitat Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
3.
4.
Zurück zum Zitat Foeldvari I, Becker I, Horneff G (2015) Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken) 67:1529–1535. doi:10.1002/acr.22613 CrossRef Foeldvari I, Becker I, Horneff G (2015) Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken) 67:1529–1535. doi:10.​1002/​acr.​22613 CrossRef
5.
6.
Zurück zum Zitat Kotaniemi K, Kautiainen H, Karma A et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108:2071–2075CrossRefPubMed Kotaniemi K, Kautiainen H, Karma A et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108:2071–2075CrossRefPubMed
7.
Zurück zum Zitat Heiligenhaus A, Niewerth M, Ganser G et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford, England) 46:1015–1019. doi:10.1093/rheumatology/kem053 CrossRef Heiligenhaus A, Niewerth M, Ganser G et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford, England) 46:1015–1019. doi:10.​1093/​rheumatology/​kem053 CrossRef
8.
Zurück zum Zitat Edelsten C, Lee V, Bentley CR et al (2002) An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 86:51–56CrossRefPubMedPubMedCentral Edelsten C, Lee V, Bentley CR et al (2002) An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 86:51–56CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Edelsten C, Reddy MA, Stanford MR et al (2003) Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 135:676–680CrossRefPubMed Edelsten C, Reddy MA, Stanford MR et al (2003) Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 135:676–680CrossRefPubMed
12.
Zurück zum Zitat Gregory AC, Kempen JH, Daniel E et al (2013) Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 120:186–192. doi:10.1016/j.ophtha.2012.07.052 CrossRefPubMed Gregory AC, Kempen JH, Daniel E et al (2013) Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 120:186–192. doi:10.​1016/​j.​ophtha.​2012.​07.​052 CrossRefPubMed
14.
Zurück zum Zitat Heiligenhaus A, Foeldvari I, Edelsten C et al (2012) Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken) 64:1365–1372. doi:10.1002/acr.21674 CrossRef Heiligenhaus A, Foeldvari I, Edelsten C et al (2012) Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken) 64:1365–1372. doi:10.​1002/​acr.​21674 CrossRef
15.
16.
Zurück zum Zitat Heiligenhaus A, Michels H, Schumacher C et al (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32:1121–1133CrossRefPubMed Heiligenhaus A, Michels H, Schumacher C et al (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32:1121–1133CrossRefPubMed
17.
Zurück zum Zitat Simonini G, Druce K, Cimaz R et al (2014) Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 66:1073–1084. doi:10.1002/acr.22214 CrossRef Simonini G, Druce K, Cimaz R et al (2014) Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 66:1073–1084. doi:10.​1002/​acr.​22214 CrossRef
20.
Zurück zum Zitat Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed
21.
Zurück zum Zitat Ruperto N, Ravelli A, Falcini F, Italian Pediatric Rheumatology Study Group et al (1998) Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 57:38–41CrossRefPubMedPubMedCentral Ruperto N, Ravelli A, Falcini F, Italian Pediatric Rheumatology Study Group et al (1998) Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 57:38–41CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Foeldvari I, Nielsen S, Kümmerle-Deschner J et al (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146–1150PubMed Foeldvari I, Nielsen S, Kümmerle-Deschner J et al (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146–1150PubMed
24.
Zurück zum Zitat Doycheva D, Zierhut M, Blumenstock G et al (2014) Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol 98:523–528. doi:10.1136/bjophthalmol-2013-303935 CrossRefPubMed Doycheva D, Zierhut M, Blumenstock G et al (2014) Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol 98:523–528. doi:10.​1136/​bjophthalmol-2013-303935 CrossRefPubMed
27.
Zurück zum Zitat Simonini G, Taddio A, Cattalini M et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63:612–618. doi:10.1002/acr.20404 CrossRef Simonini G, Taddio A, Cattalini M et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63:612–618. doi:10.​1002/​acr.​20404 CrossRef
28.
Zurück zum Zitat Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40:74–79. doi:10.3899/jrheum.120583 CrossRefPubMed Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40:74–79. doi:10.​3899/​jrheum.​120583 CrossRefPubMed
29.
Zurück zum Zitat Simonini G, Taddio A, Cattalini M et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11:16. doi:10.1186/1546-0096-11-16 CrossRefPubMedPubMedCentral Simonini G, Taddio A, Cattalini M et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11:16. doi:10.​1186/​1546-0096-11-16 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat García-De-Vicuña C, Díaz-Llopis M, Salom D et al (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm 2013:560632. doi:10.1155/2013/560632 CrossRef García-De-Vicuña C, Díaz-Llopis M, Salom D et al (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm 2013:560632. doi:10.​1155/​2013/​560632 CrossRef
31.
32.
Zurück zum Zitat Schmeling H, Minden K, Foeldvari I et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66:2580–2589. doi:10.1002/art.38741 CrossRefPubMed Schmeling H, Minden K, Foeldvari I et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66:2580–2589. doi:10.​1002/​art.​38741 CrossRefPubMed
33.
Zurück zum Zitat Tarkiainen M, Tynjälä P, Vähäsalo P et al (2015) Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford, England) 54:1170–1176. doi:10.1093/rheumatology/keu457 CrossRef Tarkiainen M, Tynjälä P, Vähäsalo P et al (2015) Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford, England) 54:1170–1176. doi:10.​1093/​rheumatology/​keu457 CrossRef
Metadaten
Titel
Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis
verfasst von
Marc Breitbach
Christoph Tappeiner
Michael R. R. Böhm
Beatrix Zurek-Imhoff
Carsten Heinz
Solon Thanos
Gerd Ganser
Arnd Heiligenhaus
Publikationsdatum
30.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3497-5

Weitere Artikel der Ausgabe 1/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.